Alternate Cancer Remedies
1911 book, The Enzyme Treatment of Cancer. The Krebs and Gurchot was astounded.
reduce and the pain to leave? And what caused its toxic symptoms?
The challenge of Beard caused the young Krebs to decide he would give his life to figuring out the cancer riddle. This was when he switched from medicine to biochemistry. He eventually amassed nine years of university studies in a variety of fields. In the process, he taught himself to read French, German, Spanish, and Italian, so he could go through 17,000 scientific papers and books.
The apricot extract had been a consistent prob- lem. It contained an unaccounted toxicity. When the extract was injected into the cancerous labo- ratory animals, the tumors would definitely be- come smaller in a matter of days. But more of the animals were dying than he anticipated, and not from cancer. Krebs knew that the kernels contained amygdalin, a cyanide-bearing substance; so, when he made his next batch, he eliminated as much of the amygdalin as he could. This time the deaths among the animals decreased drastically, but so did the tumor response. It was obvious that he had years of work ahead of him, tailoring the apri- cot seed formula. They had consistently found that the purer the preparation was made, the larger the dosage could be in animals without any side effects.
As he tried to improve the method of extrac- tion, he decided that it must be the cyanide in the amygdalin which was eliminating the cancer. But what about all those other factors plus enzymes in the extract? Where did they figure into the riddle?
Could it be that the cyanide was both the bless- ing and the curse of the old extract—that selective release of cyanide at the site of the tumor inhib- ited the tumor, but that sometimes it released pre- maturely—possibly by the action of emulsin dur- ing the extraction process?
One day in 1949, Krebs, Jr., put a quantity of the apricot preparation into a test tube. He added a quantity of glycosidase—an enzyme known to be especially abundant in cancer tissue. He waited a few moments to give the two substances a chance to work on each other. Then he took a sniff. Cya- nide. The glycosidase had caused the cynanide, safely locked inside the apricot preparation—to be released.
Triumphant, he realized his theory was true! But he also knew he had smelled something very dangerous, so he ran outside and breathed deep for a time.
At this juncture, they decided to set aside the apricot kernel project—and apply themselves to Beard’s theory.
The Krebs, Sr.; Krebs, Jr.; and Gurchot col- laboration team set to work on chymotrypsin, the pancreatic enzyme that Beard said was the blocker of the trophoblast—and cancer. In 1943, they de- veloped the first crystalline chymotrypsin commer- cially available in the world.
They sent it out to physicians who tried it out. Gurchot (in Chicago at the time) tried it on 50 or 60 patients, and only one made a complete recov- ery.
In 1947, Krebs, Sr., publicly announced 30 characteristics shared by the tropoblast cell and the cancer cell, noted the specific antithesis of chy- motrypsin to cancer cells. By 1950, the two Krebs, with the help of a Texas biochemist, Howard Beard (no relation to John Beard), published their landbook, The Unitarian or Trophoblastic Thesis of Cancer, in the Medical Record.
But the chymotrypsin experiments were not succeeding. The patients would improve, but the symptoms return. So Krebs, Jr., made a major decision: He dropped the pancreatic enzyme project,—and returned to that earlier apricot ker- nel extract his father had used.
But what in that extract caused the tumors to
They had solved the mystery.
Here is the solution to the riddle: Laetrile (amygdalin, vitamin B17) is a cya- nide-containing compound that gives up its cya- nide only in the presence of a certain enzyme group, called beta glucosidase or glucu- ronidase. But the miracle of nature is that this particular enzyme group is only found (to any appreciable extent) in cancer tissue.
When it is found elsewhere, it is always ac- companied by greater quantities of another en- zyme, called rhodanese, which has the capac- ity to convert the cyanide immediately into com- pletely harmless substances (some of which help produce and utilize other vitamins). But can- cer tissue does not have this protecting enzyme.
So cancer tissue is especially defenseless against laetrile for two reasons: (1) It has beta glucosidase, which laetrile releases its locked- in cyanide in the presence of, and (2) it does not have the enzyme, rhodanese, which pro- tects non-cancer cells by converting the cya- nide immediately into harmless substances.
The result is that the cancer cells are de- stroyed by laetrile, whereas the non-malignant cells are not harmed.
At this point, two intriguing facts stand out. First, Beard’s theory, that pancreatic enzyme would